Kathleen M.M. Vanni

1.3k total citations
41 papers, 557 citations indexed

About

Kathleen M.M. Vanni is a scholar working on Infectious Diseases, Rheumatology and Neurology. According to data from OpenAlex, Kathleen M.M. Vanni has authored 41 papers receiving a total of 557 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Infectious Diseases, 13 papers in Rheumatology and 11 papers in Neurology. Recurrent topics in Kathleen M.M. Vanni's work include COVID-19 Clinical Research Studies (17 papers), Rheumatoid Arthritis Research and Therapies (10 papers) and Long-Term Effects of COVID-19 (10 papers). Kathleen M.M. Vanni is often cited by papers focused on COVID-19 Clinical Research Studies (17 papers), Rheumatoid Arthritis Research and Therapies (10 papers) and Long-Term Effects of COVID-19 (10 papers). Kathleen M.M. Vanni collaborates with scholars based in United States, France and China. Kathleen M.M. Vanni's co-authors include Jeffrey A. Sparks, Daniel H. Solomon, Grace Qian, Emily Kowalski, Zachary S. Wallace, Naomi J. Patel, Claire Cook, Xiaoqing Fu, Xiaosong Wang and Houchen Lyu and has published in prestigious journals such as Journal of the American Society of Nephrology, Science Translational Medicine and Frontiers in Immunology.

In The Last Decade

Kathleen M.M. Vanni

39 papers receiving 549 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kathleen M.M. Vanni United States 16 198 169 132 100 73 41 557
Sabine Mainbourg France 10 194 1.0× 110 0.7× 77 0.6× 86 0.9× 35 0.5× 31 494
C. Grangé France 12 139 0.7× 53 0.3× 60 0.5× 86 0.9× 34 0.5× 29 563
Cristina Rosário Portugal 6 163 0.8× 185 1.1× 78 0.6× 24 0.2× 71 1.0× 10 603
Linlin Cheng China 11 240 1.2× 97 0.6× 96 0.7× 101 1.0× 113 1.5× 46 628
Hervé Lobbes France 9 164 0.8× 52 0.3× 63 0.5× 62 0.6× 22 0.3× 25 358
Augustine Manadan United States 14 185 0.9× 259 1.5× 35 0.3× 24 0.2× 49 0.7× 58 747
Xuerong Deng China 13 50 0.3× 326 1.9× 45 0.3× 54 0.5× 24 0.3× 42 511
Marco Fornaro Italy 13 67 0.3× 224 1.3× 44 0.3× 29 0.3× 65 0.9× 56 481
Christina Price United States 12 166 0.8× 71 0.4× 86 0.7× 134 1.3× 107 1.5× 27 652
Gunnar Strandberg Sweden 9 59 0.3× 316 1.9× 38 0.3× 54 0.5× 27 0.4× 24 518

Countries citing papers authored by Kathleen M.M. Vanni

Since Specialization
Citations

This map shows the geographic impact of Kathleen M.M. Vanni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kathleen M.M. Vanni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kathleen M.M. Vanni more than expected).

Fields of papers citing papers by Kathleen M.M. Vanni

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kathleen M.M. Vanni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kathleen M.M. Vanni. The network helps show where Kathleen M.M. Vanni may publish in the future.

Co-authorship network of co-authors of Kathleen M.M. Vanni

This figure shows the co-authorship network connecting the top 25 collaborators of Kathleen M.M. Vanni. A scholar is included among the top collaborators of Kathleen M.M. Vanni based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kathleen M.M. Vanni. Kathleen M.M. Vanni is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Hayashi, Keigo, Pierre‐Antoine Juge, Gregory C McDermott, et al.. (2024). Forced vital capacity trajectories and risk of lung transplant and ILD-related mortality among patients with rheumatoid arthritis-associated interstitial lung disease. Clinical Rheumatology. 43(8). 2453–2466. 3 indexed citations
3.
Zhang, Qianru, Gregory C McDermott, Pierre‐Antoine Juge, et al.. (2024). Disease-modifying antirheumatic drugs and risk of incident interstitial lung disease among patients with rheumatoid arthritis: A systematic review and meta-analysis. Seminars in Arthritis and Rheumatism. 69. 152561–152561. 4 indexed citations
4.
Patel, Naomi J., Xiaosong Wang, Lin Miao, et al.. (2024). Factors Associated With an Electronic Health Record–Based Definition of Postacute Sequelae of COVID-19 in Patients With Systemic Autoimmune Rheumatic Disease. The Journal of Rheumatology. 51(5). 529–537. 2 indexed citations
5.
Herman, Jonathan D., Caroline Atyeo, Claire Cook, et al.. (2023). Humoral immunity to an endemic coronavirus is associated with postacute sequelae of COVID-19 in individuals with rheumatic diseases. Science Translational Medicine. 15(712). eadf6598–eadf6598. 9 indexed citations
6.
Juge, Pierre‐Antoine, Keigo Hayashi, Gregory C McDermott, et al.. (2023). Effectiveness and tolerability of antifibrotics in rheumatoid arthritis-associated interstitial lung disease. Seminars in Arthritis and Rheumatism. 64. 152312–152312. 16 indexed citations
7.
Hanberg, Jennifer S., Xiaoqing Fu, Xiaosong Wang, et al.. (2023). Effectiveness of a fourth dose of COVID-19 mRNA vaccine in patients with systemic autoimmune rheumatic diseases using disease-modifying antirheumatic drugs: an emulated target trial. The Lancet Rheumatology. 6(1). e21–e30. 7 indexed citations
8.
Qian, Grace, Xiaosong Wang, Naomi J. Patel, et al.. (2023). Outcomes with and without outpatient SARS-CoV-2 treatment for patients with COVID-19 and systemic autoimmune rheumatic diseases: a retrospective cohort study. The Lancet Rheumatology. 5(3). e139–e150. 31 indexed citations
9.
Wang, Xiaosong, Kazuki Yoshida, Grace Qian, et al.. (2023). Immunomodulator use, risk factors and management of flares, and mortality for patients with pre-existing rheumatoid arthritis after immune checkpoint inhibitors for cancer. Seminars in Arthritis and Rheumatism. 64. 152335–152335. 9 indexed citations
10.
Cook, Claire, Naomi J. Patel, Xiaoqing Fu, et al.. (2023). Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines Against COVID-19 Infection Among Patients With Systemic Autoimmune Rheumatic Diseases on Immunomodulatory Medications. The Journal of Rheumatology. 50(5). 697–703. 5 indexed citations
11.
Wang, Xiaosong, Naomi J. Patel, Yumeko Kawano, et al.. (2023). Associations of DMARDs with post-acute sequelae of COVID-19 in patients with systemic autoimmune rheumatic diseases: a prospective study. Lara D. Veeken. 63(10). 2828–2837. 3 indexed citations
12.
Figueroa‐Parra, Gabriel, Emily Gilbert, Maria O Valenzuela-Almada, et al.. (2022). Risk of severe COVID-19 outcomes associated with rheumatoid arthritis and phenotypic subgroups: a retrospective, comparative, multicentre cohort study. The Lancet Rheumatology. 4(11). e765–e774. 27 indexed citations
13.
Patel, Naomi J., Xiaosong Wang, Xiaoqing Fu, et al.. (2022). Factors associated with COVID-19 breakthrough infection among vaccinated patients with rheumatic diseases: A cohort study. Seminars in Arthritis and Rheumatism. 58. 152108–152108. 25 indexed citations
14.
15.
Kawano, Yumeko, Naomi J. Patel, Xiaosong Wang, et al.. (2022). Temporal trends in COVID-19 outcomes among patients with systemic autoimmune rheumatic diseases: from the first wave through the initial Omicron wave. Annals of the Rheumatic Diseases. 81(12). 1742–1749. 24 indexed citations
16.
Solomon, Daniel H., Jon T. Giles, Katherine P. Liao, et al.. (2022). Reducing cardiovascular risk with immunomodulators: a randomised active comparator trial among patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. 82(3). 324–330. 43 indexed citations
17.
Patel, Naomi J., Claire Cook, Kathleen M.M. Vanni, et al.. (2022). Impact of vaccination on postacute sequelae of SARS CoV-2 infection in patients with rheumatic diseases. Annals of the Rheumatic Diseases. 82(4). 565–573. 13 indexed citations
18.
Cunningham‐Bussel, Amy, Jiaqi Wang, Lauren Prisco, et al.. (2021). Predictors of Rheumatic Immune‐Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer. Arthritis & Rheumatology. 74(3). 527–540. 29 indexed citations
19.
20.
Tedeschi, Sara K., et al.. (2019). A prospective study of dual-energy CT scanning, US and X-ray in acute calcium pyrophosphate crystal arthritis. Lara D. Veeken. 59(4). 900–903. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sabine Mainbourg Breakdown of academic impact, for papers by C. Grangé Breakdown of academic impact, for papers by Cristina Rosário Breakdown of academic impact, for papers by Linlin Cheng Breakdown of academic impact, for papers by Hervé Lobbes Breakdown of academic impact, for papers by Augustine Manadan Breakdown of academic impact, for papers by Xuerong Deng Breakdown of academic impact, for papers by Marco Fornaro Breakdown of academic impact, for papers by Christina Price Breakdown of academic impact, for papers by Gunnar Strandberg
Rankless by CCL
2026